Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02670915 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 834
- Enrollment target
NCT02670915 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 834 participants.
The verdict
NCT02670915, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 834 participants
- Enrollment target
Study Summary
This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of faster-acting insulin aspart compared to NovoRapid® both in combination with insulin degludec in children and adolescents with type 1 diabetes.
Interventions
- DRUG insulin aspart
- DRUG Faster-acting insulin aspart
- DRUG insulin degludec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 834 participants |
| Start Date | 2016-05-04 |
| Est. Completion | 2018-03-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02670915
The ClinicalTrials.gov registry entry for NCT02670915 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 834 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which insulin aspart is the first listed.
NCT02670915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02670915 about?
NCT02670915 is a clinical study titled "Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes". This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of faster-acting insulin aspart compared to NovoRapid® both in combination with insulin degludec in children and adolescents with type 1 diabetes.
What is the current status of trial NCT02670915?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 834 participants. The study started on 2016-05-04. Estimated completion is 2018-03-03.
What interventions are being tested in trial NCT02670915?
The interventions under investigation include: insulin aspart (DRUG), Faster-acting insulin aspart (DRUG), insulin degludec (DRUG).
Who is sponsoring clinical trial NCT02670915?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.